4 Minute read
GSK is trialling an arthritis drug that prevents the inflammation responsible for bone damage and pain. The drug is based on discoveries made by University of Melbourne researchers.
- GSK has launched Phase III clinical trials for a drug to treat hand osteoarthritis and rheumatoid arthritis.
- Osteoarthritis and rheumatoid arthritis are the two most common forms of arthritis.
- The drug is designed to prevent the inflammation that causes joint damage and pain.
Osteoarthritis and rheumatoid arthritis are the two most common forms of arthritis. It has been estimated that half of the world's population aged 65 years or older has osteoarthritis. As many as 2 per cent of people of all ages have rheumatoid arthritis.
Osteoarthritis is a degenerative disease affecting specific joints. Rheumatoid arthritis is an auto-immune disease that can affect the entire body. Although they differ in origin, their effects are similar: inflammation leads to cartilage and bone damage, and the subsequent swelling and stiffness cause pain. The associated loss of movement can reduce quality of life and increase the risk of obesity and cardiovascular disease.
Current therapies treat the symptoms rather than curing or preventing the diseases.
Professor John Hamilton, Associate Professor Andrew Cook and colleagues from the Faculty of Medicine, Dentistry and Health Sciences focused their research on a specific type of protein involved in the inflammatory immune response.
The protein, granulocyte-macrophage colony-stimulating factor (GM-CSF), stimulates the production of different cell types and then activates those cells to produce pro-inflammatory compounds.
After inducing arthritis in mice, the team found that mice without GM-CSF had less joint deformation, cartilage damage and inflammation than mice with GM-CSF. By using an antibody that inactivates GM-CSF, the researchers successfully prevented its pro-inflammatory activity in mice.
Technology development history
The researchers patented a method of treatment for their antibody technology for inflammation in the USA in 2000. Several pharmaceutical companies expressed an interest in the technology. In 2005, the University partnered with MorphoSys, which had extensive experience in developing human monoclonal antibodies.
MorphoSys obtained exclusive rights to use GM-CSF inhibitors to treat inflammatory diseases. In return, the company will provide the University of Melbourne with an upfront payment, milestone payments linked to clinical development, and a percentage royalty on net sales in the USA. In 2008, Professor Hamilton and Associate Professor Andrew Cook filed additional patents covering the use of the anti-GM-CSF antibody to treat osteoarthritis and pain. This technology was assigned to MorphoSys under similar licensing terms.
MorphoSys successfully completed a Phase I clinical trial in healthy volunteers with the anti-GM-CSF antibody (which they named MOR103) and a Phase Ib trial in individuals with multiple sclerosis.
A Phase I/II trial in patients with rheumatoid arthritis demonstrated that MOR103 is the first antibody against GM-CSF to safely and effectively treat this disease. (Phase I clinical trials test the safety, side effects, dose and formulation of a particular treatment. Phase II clinical trials evaluate its effects. Phase III clinical trials test a new treatment against standard treatments.)
In 2013, MorphoSys sublicensed the technology to GSK for an upfront payment of €22.5 million, milestone payments of up to €423 million, and double-digit royalties on net sales.
GSK assumed exclusive responsibility for the development and commercialisation of MOR103, which they renamed GSK3196165. After reformulating the technology, the company completed three Phase II clinical trials in hand osteoarthritis and rheumatoid arthritis in 2018.
In 2019, GSK embarked on a Phase III clinical program (ContRAst) to compare the treatment, now called otilimab, against two drugs in patients with rheumatoid arthritis who have not responded to, or cannot tolerate, current treatments. The four trials in this clinical program will treat patients over periods of 6 months to 4 years. The launch of the Phase III trials triggered a €22 million milestone payment to MorphoSys.
Cook AD, Pobjoy J, Steidl S, Dürr M, Braine EL, Turner AL, Lacey DC, Hamilton JA (2012) Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development. Arthritis Research and Therapy 14: R199. doi: 10.1186/ar4037
Hamilton JA, Anderson GP (2004) GM-CSF biology. Growth Factors 22(4): 225–231. doi: 10.1080/08977190412331279881
Cook AD, Braine EL, Campbell IK, Rich MJ, Hamilton JA (2001) Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Research and Therapy 3(5): 293–298. doi: 10.1186/ar318
US Patent no. 7,455,836, filed 8 May 2001
US Patent no. 8,142,777, filed 18 September 2007
PCT/AU2009/001672, filed 21 December 2009
PCT/AU2009/001671, filed 21 December 2009
First published on 27 April 2020.
Share this article
Case studyFaculty of Medicine Dentistry And Health Sciences
Why partner with us
Partner with the University of Melbourne. Join a community where the world’s best minds help solve the biggest global challenges of our time.
Collaborate with us
Explore some of the many ways you can partner with us to help your organisation excel.
Tackling severe asthma with an inhalable drug
A drug developed by Pieris Pharmaceuticals and the University of Melbourne uses anticalin technology to treat severe asthma.
Brain implants to predict and prevent seizures
A Carbon Cybernetics implant that stimulates and records information from single brain cells is being developed to help manage epilepsy.